Cargando…
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers
Many epithelial cancers rely on enhanced expression of the epidermal growth factor receptor (EGFR) to drive proliferation and survival pathways. Development of therapeutics to target EGFR signaling has been of high importance, and multiple examples have been approved for human use. However, many of...
Autores principales: | Simon, Nathan, FitzGerald, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885052/ https://www.ncbi.nlm.nih.gov/pubmed/27153091 http://dx.doi.org/10.3390/toxins8050137 |
Ejemplares similares
-
Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013) -
Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P
por: Mattoo, Abid R., et al.
Publicado: (2013) -
Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors
por: Pilbeam, Kristy, et al.
Publicado: (2017) -
The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy
por: Xiang, Xinran, et al.
Publicado: (2011) -
Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)